1. Scrip
  2. >>Business

Shire Outlines Baxalta Integration Strategy

 
• By Joseph Haas

First quarter financial results brought another growth period for Shire PLC, but perhaps the most noteworthy information provided by the company on its April 29 earnings call, was its strategy for integrating Baxalta Inc. into its infrastructure, assuming both companies' boards approve the transaction when they meet separately on May 27.

Overall, the Dublin-headquartered specialty firm reported product sales of $1.627bn for the first quarter of 2016, up 14% year-over-year. As usual, the top-seller was attention-deficit/hyperactivity disorder (ADHD) stalwart Vyvanse (lisdexamfetamine), which posted 22% growth to $509m on the quarter. It also was a strong quarter for Shire's hereditary angioedema franchise, as Firazyr (icatibant) sales increased 39% to $128m and Cinryze (C1 esterase inhibitor) sales rose 11% to $164m.

Initially launched as a hostile bid in mid-2015, Shire's acquisition of Baxalta was agreed upon in January at a price of roughly $32bn, in a transaction that will leave Shire...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.